We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mixed Titer Performance Panel Accurately Tests for Dengue Virus

By LabMedica International staff writers
Posted on 28 Jun 2012
An Anti-Dengue panel is designed to help blood donor-collection facilities, diagnostics manufacturers, and clinical laboratories evaluate and spot problems with their anti-Denguevirus assays.

The new performance panel is derived from undiluted, unpreserved human plasma specimens, with 21 members representing a wide range of reactivity for anti-dengue Immunoglobulin M (IgM) and IgG antibodies, from negative to strongly positive. Panel members include samples from individuals with recent and past infection by all four dengue viruses (DENV-1 through DENV-4).

The Anti-Dengue Mixed Titer Performance Panel produced by SeraCare Life Sciences, Inc. (Milford, MA, USA) is available for purchase immediately worldwide. SeraCare's portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking, and contract research services.

Dengue fever is caused by one of four different but related viruses. It is spread by the bite of mosquitoes, most commonly the mosquito Aedes aegypti, which is found in tropic and subtropic regions. This includes parts of the Indonesian archipelago into northeastern Australia, South and Central America, Southeast Asia, Sub-Saharan Africa, and some parts of the Caribbean. Dengue fever is being seen more often in world travelers.

“Forty percent of the world’s population lives in areas at risk for dengue transmission,” said Chris Long, associate product manager at SeraCare Life Sciences. “Continued increases in global travel and immigration raise the risk of dengue virus transmission worldwide, well beyond the countries in which it is endemic. The new SeraCare Anti-Dengue Performance Panel responds to the rising world health issue and the corresponding need for assays that are well-challenged for accuracy and sensitivity.”

SeraCare panels are assembled from highly characterized natural patient samples. They are vital for assay development and regulatory compliance and provide a common reference for assay comparison and troubleshooting of existing assays.

Related Links:
SeraCare Life Sciences


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Liquid Based Cytology Production Machine
LBP-4032
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Latest Microbiology News

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Innovative Diagnostic Approach for Bacterial Infections to Enable Faster and Effective Treatment